NO20070721L - Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter - Google Patents

Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter

Info

Publication number
NO20070721L
NO20070721L NO20070721A NO20070721A NO20070721L NO 20070721 L NO20070721 L NO 20070721L NO 20070721 A NO20070721 A NO 20070721A NO 20070721 A NO20070721 A NO 20070721A NO 20070721 L NO20070721 L NO 20070721L
Authority
NO
Norway
Prior art keywords
erbb receptor
predicting
tumor
response
mammal
Prior art date
Application number
NO20070721A
Other languages
English (en)
Norwegian (no)
Inventor
Kevin Hudson
Marie Caroline South
Gayle Marshall
Mehran Sam
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20070721L publication Critical patent/NO20070721L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20070721A 2004-07-23 2007-02-08 Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter NO20070721L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59035704P 2004-07-23 2004-07-23
US61902704P 2004-10-18 2004-10-18
PCT/GB2005/002852 WO2006008526A2 (fr) 2004-07-23 2005-07-20 Procede

Publications (1)

Publication Number Publication Date
NO20070721L true NO20070721L (no) 2007-04-20

Family

ID=35107052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070721A NO20070721L (no) 2004-07-23 2007-02-08 Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter

Country Status (11)

Country Link
US (1) US20080286771A1 (fr)
EP (1) EP1781815A2 (fr)
JP (1) JP2008507264A (fr)
AU (1) AU2005263972A1 (fr)
BR (1) BRPI0513589A (fr)
CA (1) CA2574311A1 (fr)
IL (1) IL180333A0 (fr)
MX (1) MX2007000944A (fr)
NO (1) NO20070721L (fr)
TW (1) TW200621998A (fr)
WO (1) WO2006008526A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
WO2007101122A2 (fr) * 2006-02-24 2007-09-07 University Of Chicago Procedes et compositions impliquant slc17a1
EP2209495A4 (fr) * 2007-10-04 2012-05-02 Agency Science Tech & Res Taz/wwtr1 pour diagnostic et traitement de cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en) * 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
CA2725598C (fr) 2008-06-17 2013-10-08 Wyeth Llc Combinaisons antineoplasiques contenant du hki-272 et de la vinorelbine
WO2010017163A1 (fr) 2008-08-04 2010-02-11 Wyeth Combinaisons antinéoplasiques de 4-anilino-3-cyanoquinoléines et de capécitabine
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
CA2838086A1 (fr) * 2011-06-02 2012-12-06 Almac Diagnostics Limited Test de diagnostic moleculaire pour un cancer
WO2014087156A1 (fr) 2012-12-03 2014-06-12 Almac Diagnostics Limited Essai de diagnostic moléculaire pour cancer
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003238871B2 (en) * 2002-06-05 2009-04-23 Cedars-Sinai Medical Center Method of treating cancer using kinase inhibitors
JP2007530954A (ja) * 2004-03-26 2007-11-01 ブリストル−マイヤーズ　スクイブ　カンパニー 非小細胞肺癌において上皮細胞増殖因子レセプターモジュレーターに対する感受性を決定するためのバイオマーカーおよび方法

Also Published As

Publication number Publication date
AU2005263972A1 (en) 2006-01-26
TW200621998A (en) 2006-07-01
WO2006008526A2 (fr) 2006-01-26
JP2008507264A (ja) 2008-03-13
US20080286771A1 (en) 2008-11-20
EP1781815A2 (fr) 2007-05-09
CA2574311A1 (fr) 2006-01-26
MX2007000944A (es) 2007-04-13
WO2006008526A3 (fr) 2006-07-13
IL180333A0 (en) 2007-07-04
BRPI0513589A (pt) 2008-05-13

Similar Documents

Publication Publication Date Title
NO20070721L (no) Metode for a forutsi responsen til en tumor overfor ERBB-reseptor medikamenter
Pyke et al. Evolutionary pressure against MHC class II binding cancer mutations
Cheng et al. Thymic tolerance as a key brake on autoimmunity
Alfano et al. The impact of air pollution on our epigenome: how far is the evidence?(a systematic review)
NZ600235A (en) Methods and compositions for the assessment of drug response
Chess Mechanisms and consequences of widespread random monoallelic expression
Jones et al. DNA methylation and healthy human aging
Kubota-Sakashita et al. A role of ADAR2 and RNA editing of glutamate receptors in mood disorders and schizophrenia
Halmai et al. Associations between depression severity and purinergic receptor P2RX7 gene polymorphisms
Setchell et al. The hidden benefits of sex: Evidence for MHC‐associated mate choice in primate societies
Kelly et al. Increased circulating regulatory T cells in medicated people with schizophrenia
Klengel et al. Gene× environment interactions in the prediction of response to antidepressant treatment
US10837062B2 (en) Method for predicting a treatment response to a CRHR1 antagonist and/or a V1B antagonist in a patient with depressive and/or anxiety symptoms
Logan Do you smell what I smell? Genetic variation in olfactory perception
WO2008057545A3 (fr) Identification fondée sur la détermination du profil d'expression génétique de signatures génomiques de myélomes multiples à haut risque et leurs utilisations
Haenisch et al. Genome-wide association data provide further support for an association between 5-HTTLPR and major depressive disorder
NO20070521L (no) Fremgangsmater relatert til en enkel nukleotid polymorfisme av den G-proteinkoplede reseptor, GPR40
Moran et al. Genomic resources for darters (Percidae: Etheostominae) provide insight into postzygotic barriers implicated in speciation
WO2005106041A3 (fr) Trousses et reactifs utilises pour diagnostiquer et pronostiquer des troubles genomiques
EP2730663A3 (fr) Facteurs génétiques associés au développement d'inhibiteur dans l'hémophilie A
El-Mallakh et al. The dopamine D4/D2 receptor antagonist affinity ratio as a predictor of anti-aggression medication efficacy
WO2008118415A3 (fr) Polymorphismes génétiques associés à des événements coronariens et à une réaction à un médicament, procédés de détection et utilisations de ceux-ci
Avraham et al. The noncoding genome and hearing loss
Kas et al. High‐resolution genetic mapping of mammalian motor activity levels in mice
ATE513929T1 (de) Gene mit einfluss auf die menschliche gedächtnisleistung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application